Dr. Lequerre has received consultant fees (less than $10,000) from Sobi.
Anakinra in Adult-Onset Still's Disease: Long-Term Treatment in Patients Resistant to Conventional Therapy
Article first published online: 23 APR 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis Care & Research
Volume 65, Issue 5, pages 822–826, May 2013
How to Cite
Giampietro, C., Ridene, M., Lequerre, T., Chalumeau, N. C., Amoura, Z., Sellam, J., Sibilia, J., Bourgeois, P., Fautrel, B. and on behalf of the CRI (Club Rhumatismes et Inflammation) (2013), Anakinra in Adult-Onset Still's Disease: Long-Term Treatment in Patients Resistant to Conventional Therapy. Arthritis Care Res, 65: 822–826. doi: 10.1002/acr.21901
- Issue published online: 23 APR 2013
- Article first published online: 23 APR 2013
- Accepted manuscript online: 6 DEC 2012 04:17PM EST
- Manuscript Accepted: 25 OCT 2012
- Manuscript Received: 22 MAY 2012
- University of L'Aquila, Italy
- Tunis University, Tunis, Tunisia
Anakinra is effective in adult-onset Still's disease (AOSD) in the short term, but little is known regarding its efficacy over the long term. Our objective was to assess the long-term efficacy and safety of anakinra in AOSD.
A nationwide survey was conducted between 2009 and 2010 to identify AOSD patients treated with anakinra. Collected data consisted of disease characteristics at diagnosis and at medication onset; anakinra efficacy, safety, and dose adaptation; and reasons for discontinuation, if applicable.
The study included 28 AOSD patients, with a mean age of 40.3 years and a mean disease duration at the start of anakinra of 9.3 years. All patients had previously failed to respond to steroids and disease-modifying antirheumatic drugs. All patients responded to anakinra, with a rapid and sustained decrease in steroid doses. At the last followup (mean 23 months), 16 patients were still being treated with anakinra: 4 had a partial response and 12 were in complete remission. Twelve patients had discontinued anakinra: 2 due to an insufficient response, 4 due to an AOSD flare after a period of complete remission, 2 due to side effects, and 1 due to a desire for pregnancy. In 3 patients, the drug discontinuation was possible because they achieved complete remission. Six additional patients experienced anakinra dose tapering, with sustained remission in 2 and relapse in the others. Anakinra was well tolerated and adverse events were rated as mild.
Anakinra was consistently efficacious in AOSD and displayed good therapeutic maintenance. Anakinra dose tapering or discontinuation was associated with relapse in half of the patients.